Top Results For: VIDO-InterVac

In the first of a three-part series, Chris Carr speaks with VIDO CEO Dr. Volker Gerdts about how the facility has evolved since the pandemic.

Zyus Life Sciences has teamed up with VIDO-InterVac to use plant cells to create a potential vaccine component for COVID-19 as an alternative to animals.

The director of the University of Saskatchewan’s VIDO-Intervac is celebrating a new investment in the lab.

University of Saskatchewan’s VIDO-InterVac team has seen promising results in their clinical trials for a COVID-19 vaccine.

VIDO-InterVac director and CEO Dr. Volker Gerdts joins Global Morning News to share the next steps in the process following a major milestone in their development of a potential COVID-19 vaccine.

A day after the Pfizer COVID-19 vaccine was approved for use in Canada, VIDO-InterVac is hitting a milestone with their Saskatoon-made vaccine – filing an application to start human clinical trials.

Saskatchewan researchers and scientists are stepping up to help Canada and the rest of the world get back to the way life was. Kyle Benning sits down with VIDO-InterVac’s director to discuss the progress of its homegrown vaccine.

Director and CEO of VIDO-InterVac, Dr. Volker Gerdis, joins us to talk about how they are creating a vaccine.

The Vaccine and Infectious Disease Organization – International Vaccine Centre (VIDO-InterVac) is receiving $23.3 million in federal funding in the fight against COVID-19.

USask President Peter Stoicheff joins Global News Morning with the latest on campus, including the changes to the winter semester due to the Omicron variant, and ongoing work at VIDO-InterVac.

VIDO executive director Dr. Volker Gerdts provides an update on the current upgrades to the Saskatoon facility.

VIDO-InterVac’s role was heightened two years ago as COVID-19 emerged. Director and CEO Dr. Volker Gerdts joins Global News Morning to look back at what’s changed, and looking towards the future.

VIDO-InterVac director and CEO Dr. Volker Gerdts tells Global News Morning they are trialling their Saskatoon-made COVID-19 vaccine in Africa — and gives his thoughts on the Omicron variant.

University of Saskatchewan president Peter Stoicheff joins Global News Morning to talk about the latest on campus, including vaccination rates, VIDO-InterVac and Huskies Athletics.

VIDO-InterVac director Dr. Volker Gerdts joins Global News Morning for an update on their COVID-19 vaccine research, along with recent funding for antiviral research.

VIDO-InterVac has made progress with the testing of their coronavirus vaccine on ferrets. Dr. Volker Gerdts joins us to discuss the what the early results are dictating and when we should expect a potential vaccine.

Saskatoon’s VIDO-Intervac lab is getting ready to test a COVID-19 vaccine on living animals. Their test-creatures of choice: ferrets.

VIDO-InterVac will be speaking to the city on their plans to expand to a level 4 containment lab, Executive Director and CEO Dr. Volker Gerdts joins Global News Morning with what that expansion means.

A major milestone for vaccine development in Saskatchewan, with a new manufacturing facility opening at the University of Saskatchewan. VIDO-Intervac is now one step closer to leading Canada’s vaccine development. Easton Hamm explains how this facility hopes to play a role in preventing future pandemics.

VIDO-InterVac Director and CEO Dr. Volker Gerdts joins Global News Morning to discuss where $59 million in federal funding will go to, along with an update on their vaccine trial.